List of Excipients in Branded Drug KLOR CON M

Generic Drugs Containing KLOR CON M

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY Inc dba Vangard Labs	potassium chloride	0615-5559	CELLULOSE, MICROCRYSTALLINE
NCS HealthCare of KY Inc dba Vangard Labs	potassium chloride	0615-5559	CROSCARMELLOSE SODIUM
NCS HealthCare of KY Inc dba Vangard Labs	potassium chloride	0615-5559	ETHYLCELLULOSES

What are the Most Frequently-Used Excipients in KLOR CON M?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	ETHYLCELLULOSES

KLOR-CON M Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Klor-Con M is a microencapsulated, extended-release potassium chloride tablet marketed in 10 mEq and 20 mEq strengths. Its commercial value depends less on active-ingredient exclusivity than on release control, gastrointestinal tolerability, manufacturing consistency, regulatory substitutability, and supply reliability. The core opportunity is to develop potassium chloride products that match or improve Klor-Con M's release profile while reducing excipient, coating, packaging, or manufacturing costs.

What is Klor-Con M and how does its formulation work?

Klor-Con M contains potassium chloride in a microencapsulated extended-release matrix. The product is designed to release potassium chloride gradually rather than deliver an immediate bolus of concentrated potassium to the gastrointestinal tract.

The label identifies Klor-Con M as an extended-release tablet indicated for the treatment and prevention of potassium depletion when dietary or therapeutic replacement is appropriate. The product is not intended for patients with conditions such as hyperkalemia or severe renal impairment without appropriate clinical oversight (FDA, 2024a).

Klor-Con M dosage forms and strengths

Product	Potassium chloride strength	Dosage form	Release type
Klor-Con M10	10 mEq	Extended-release tablet	Microencapsulated
Klor-Con M20	20 mEq	Extended-release tablet	Microencapsulated

Klor-Con M tablets are generally swallowed whole with meals and water. The prescribing information warns against crushing, chewing, or sucking the tablets because these actions may disrupt the intended release characteristics and increase localized potassium exposure (FDA, 2024a).

What excipients are used in Klor-Con M?

Klor-Con M uses excipients that support microencapsulation, granule formation, tablet compression, flow, lubrication, and film coating. The exact qualitative and quantitative composition can vary by strength, manufacturing site, and approved product version.

Public labeling identifies excipient classes associated with the product, including:

• Ethylcellulose or another release-controlling polymer
• Povidone or related binder
• Microcrystalline cellulose
• Silicon dioxide or another glidant
• Magnesium stearate
• Film-coating materials, which may include hypromellose, polyethylene glycol, titanium dioxide, and related coating components

The commercial formulation logic is straightforward: potassium chloride is highly water soluble and can produce high local concentrations in the gastrointestinal tract. A polymer coating or microencapsulation layer moderates dissolution and distributes the salt across multiple particles. Tablet excipients then provide mechanical strength and manufacturing control.

Excipient functions in a microencapsulated potassium chloride tablet

Excipient category	Primary function	Commercial significance
Release-control polymer	Slows potassium chloride dissolution	Determines dissolution profile and food-effect behavior
Binder	Improves granule and tablet integrity	Reduces friability and manufacturing failures
Microcrystalline cellulose	Provides compression and bulk	Supports tablet hardness at high drug loading
Glidant	Improves powder flow	Supports weight uniformity and production throughput
Lubricant	Reduces sticking and ejection force	Limits tooling damage and tablet defects
Film coating	Improves swallowability and handling	Can affect moisture protection and release
Pigment/opacifier	Controls appearance and light protection	Supports product identification and packaging

How strong is the excipient strategy for Klor-Con M?

The formulation strategy is commercially credible because potassium chloride creates a difficult high-dose formulation problem. A 20 mEq tablet contains a substantial quantity of potassium chloride relative to the total tablet mass. The formulation must maintain adequate drug loading while controlling dissolution and avoiding excessive tablet size.

The principal technical barriers are:

1. Uniform coating of potassium chloride particles.
2. Consistent polymer thickness across production batches.
3. Control of dissolution over the full shelf life.
4. Adequate tablet hardness without delaying release excessively.
5. Prevention of dose dumping after mechanical damage.
6. Control of moisture uptake and coating defects.
7. Maintenance of release performance after exposure to food.

The excipient estate is therefore more important as process know-how than as a list of ingredients. Many individual excipients are compendial or widely used. Competitive differentiation is more likely to arise from polymer grade, coating weight, particle-size distribution, spray parameters, curing conditions, granulation method, and dissolution specifications.

Which excipient attributes create the greatest technical risk?

Ethylcellulose and other hydrophobic polymers can materially affect release when particle size, viscosity grade, coating porosity, or coating weight changes. Povidone can improve granule strength but may alter water penetration and drug release if used at a different concentration. Magnesium stearate can reduce wetting when over-lubrication occurs. Film-coating changes can affect tablet integrity, moisture exposure, and patient acceptability.

For an ANDA sponsor, the risk is not that any single excipient is unavailable. The risk is that a seemingly minor formulation change can produce a dissolution profile that is not comparable to the reference product.

What regulatory requirements apply to Klor-Con M generics?

Generic Klor-Con M products would generally be pursued through the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The sponsor must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, subject to FDA requirements for the specific product (FDA, 2023a).

Pharmaceutical equivalence

A competing product normally must match the reference product in:

• Active ingredient
• Strength
• Dosage form
• Route of administration
• Release characteristics
• Applicable labeling requirements

For potassium chloride extended-release tablets, excipient sameness is not necessarily required. FDA generally permits different inactive ingredients when the formulation meets applicable safety, quality, and bioequivalence requirements. The FDA Inactive Ingredient Database provides precedent regarding prior use of excipients in approved drug products, but it does not eliminate the need to justify the proposed formulation (FDA, 2024b).

Bioequivalence and dissolution

A generic sponsor should expect close scrutiny of:

• Comparative dissolution across multiple media
• Release at early, middle, and late time points
• Tablet robustness after mechanical stress
• Food-effect behavior
• In vitro release under discriminatory conditions
• Batch-to-batch consistency
• Stability through the proposed shelf life

For an extended-release potassium product, a fast initial release may raise dose-dumping concerns. A slow or incomplete release may create concerns over therapeutic availability. The sponsor's development program must therefore optimize the entire release curve rather than target only one dissolution endpoint.

What patent and exclusivity barriers affect Klor-Con M?

Klor-Con M is a small-molecule potassium chloride product, not a biologic. Biosimilar pathways and biologic patent-linkage rules do not apply.

The main legal routes for competition are:

• ANDA approval with Paragraph IV certification against any listed patents
• ANDA approval with a Paragraph III certification where a listed patent remains in force
• A 505(b)(2) application for a materially different formulation, delivery system, or clinical use
• Post-expiration or non-infringing entry based on the absence of relevant enforceable patent claims

The key patent risk is formulation coverage. A patent directed broadly to potassium chloride is unlikely to create a durable barrier because potassium chloride is an established active ingredient. More relevant claims would cover:

• Specific polymer-coated potassium chloride particles
• Defined coating thickness or polymer ratios
• Release profiles
• Particle-size distributions
• Manufacturing processes
• Tablet structures
• Reduced gastrointestinal irritation
• Combination products or specific dosing regimens

The FDA Orange Book remains the controlling public source for listed patents, exclusivity, and reference listed drug information. Sponsors should evaluate the current Orange Book entry and associated patent certifications before relying on a no-patent or patent-expired launch assumption (FDA, 2024c).

Does Klor-Con M have biologic or biosimilar risk?

No. Klor-Con M contains a chemically synthesized small-molecule electrolyte. Its competitive risk comes from generic tablets, capsules, liquids, powders, and alternative potassium replacement products, not biosimilars.

When does Klor-Con M lose exclusivity?

The product's practical exclusivity is driven primarily by formulation patents, regulatory exclusivity, manufacturing know-how, and market access. Potassium chloride has been marketed for decades, so the active ingredient itself does not create meaningful exclusivity. Any current patent or exclusivity assessment must be based on the contemporaneous Orange Book record and applicable FDA approvals.

What formulation opportunities compete with Klor-Con M?

The strongest opportunities are products that preserve controlled release while improving administration, tolerability, or manufacturing economics.

Lower-cost extended-release tablets

A generic tablet can compete through:

• Lower polymer consumption
• Higher coating efficiency
• Reduced tablet weight
• Fewer manufacturing steps
• More efficient packaging
• Contract manufacturing in lower-cost facilities

The product must maintain the reference release profile. Cost reduction that produces a materially different dissolution curve could create regulatory or clinical risk.

Smaller or easier-to-swallow tablets

Potassium chloride tablets can be difficult for patients to swallow, particularly in older adults and patients taking multiple medicines. Opportunities include:

• Smaller tablets at equivalent strength
• Improved film coating
• Bilayer or multilayer tablets
• Multiparticulate capsules
• Sprinkle formulations, if supported by appropriate labeling and bioequivalence data

A smaller tablet may require higher drug loading, more efficient granulation, or a different particle-coating approach.

Liquid and powder formulations

Liquid potassium chloride products compete in patients who cannot swallow tablets. Their advantages include dose flexibility and suitability for enteral administration. Their disadvantages include taste, dosing-measurement errors, packaging complexity, and concentrated local exposure if inadequately diluted.

A powder or sachet formulation could offer lower shipping weight and flexible dosing. The principal technical challenge is taste masking without delaying dissolution or creating unacceptable osmolality.

Gastrointestinal tolerability products

A formulation that reduces local potassium concentration may have commercial value if supported by appropriate comparative evidence. Potential approaches include:

• Smaller coated particles
• More uniform dispersion in the gastrointestinal tract
• Lower peak local concentration
• Improved tablet disintegration after the controlled-release phase
• Combination with administration instructions that reduce irritation

Marketing claims must remain consistent with approved labeling and clinical evidence. Excipients alone cannot support a superiority claim without appropriate data.

What commercial opportunities exist for Klor-Con M competitors?

The commercial opportunity is strongest in generic substitution, institutional supply, and differentiated administration formats.

Opportunity	Buyer need	Relevant formulation lever
Standard generic tablet	Lower acquisition cost	Matching release with lower COGS
Hospital supply	Reliable availability	Dual sourcing and inventory resilience
Long-term-care supply	Easier administration	Smaller tablets or alternative dosage forms
Retail pharmacy	Automatic substitution	AB-rated generic status
Specialty dispensing	Flexible dosing	Liquid, powder, or multiparticulate format
Value-based contracting	Fewer adverse administration events	Tolerability and adherence data
Private-label product	Margin and channel control	Contract manufacturing and packaging

Revenue exposure for an incumbent is most vulnerable when several ANDA-approved competitors obtain pharmacy substitution status. The first approved generic may capture disproportionate volume through wholesaler contracts and preferred formulary placement. Later entrants generally compete on price, supply continuity, packaging, and dosage-form differentiation.

What manufacturing and supply-chain barriers affect excipient strategy?

The active ingredient, potassium chloride, is widely available. The more significant supply risks involve:

• Pharmaceutical-grade release-control polymers
• Coating equipment capacity
• Consistent polymer viscosity grades
• Magnesium stearate and glidant quality
• Coating-pan throughput
• Moisture-controlled packaging
• Qualified secondary suppliers

A formulation that depends on a narrow polymer grade may face change-control delays if the supplier discontinues the material. A robust commercial strategy should qualify multiple excipient sources or establish justified material specifications broad enough to preserve supply without compromising dissolution.

Packaging also matters. High-barrier bottles, desiccants, induction seals, and unit-dose blister systems can reduce moisture exposure and improve institutional handling. Unit-dose packaging may increase cost but support hospital and long-term-care procurement.

What litigation and settlement issues should generic sponsors review?

A generic sponsor should review:

• Current Orange Book patent listings
• Patent certifications submitted by earlier ANDA applicants
• Any paragraph IV notices
• Hatch-Waxman litigation involving the reference product
• Consent judgments or settlement agreements
• Any 180-day exclusivity holder
• FDA tentative and final approval dates
• Whether a listed patent claims the tablet, coating, release profile, or method of use

Because potassium chloride is an established product, litigation risk is more likely to focus on formulation or process claims than on active-ingredient composition. A settlement could delay entry, grant a license, or establish an agreed launch date. The commercial value of an early-entry position depends on whether the first approved ANDA receives 180-day exclusivity and how many applicants are positioned to enter afterward.

How does Klor-Con M compare with other potassium replacement products?

Product category	Main advantage	Main limitation	Excipient opportunity
Klor-Con M-type ER tablet	Controlled release and established use	Swallowing difficulty	Lower-cost coating and smaller tablet
Immediate-release liquid	Flexible dosing	Taste and dosing errors	Taste masking and dosing-device design
Powder or packet	Flexible strength and transport	Reconstitution and palatability	Flavor, solubility, and osmolality control
ER capsule	Multiparticulate delivery	Higher manufacturing complexity	Particle coating and capsule filling
Intravenous potassium chloride	Rapid clinical correction	Hospital administration and monitoring	Limited oral-excipient relevance

Klor-Con M's principal competitive position is between immediate-release liquids and higher-complexity multiparticulate systems. A tablet competitor can win on price. A capsule, liquid, or powder can win on administration flexibility.

Key Takeaways

• Klor-Con M is a microencapsulated, extended-release potassium chloride tablet available in 10 mEq and 20 mEq strengths.
• The commercial formulation advantage comes from controlled release, not active-ingredient exclusivity.
• Release-control polymers, coating weight, particle size, lubrication, and moisture control are the key excipient variables.
• Generic competition is likely to depend on dissolution matching, bioequivalence, manufacturing cost, and substitution status.
• The most valuable formulation opportunities are smaller tablets, improved swallowability, multiparticulate capsules, powders, and better-tolerated liquid products.
• Patent risk is likely to center on formulation, release profile, and manufacturing claims rather than potassium chloride itself.
• Biosimilar risk does not apply because Klor-Con M is a small-molecule electrolyte product.
• Supply resilience for specialty polymers and coating capacity can create a commercial advantage even where the active ingredient is commoditized.

FAQs

Can Klor-Con M excipients be copied exactly by a generic manufacturer?

Not necessarily. A generic sponsor may use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, and quality. Exact excipient copying can simplify development but does not guarantee equivalent release.

Which excipient is most important for potassium chloride extended release?

The release-control polymer and its coating process are usually the most important. Polymer type, viscosity, coating thickness, porosity, and curing conditions can materially change potassium chloride dissolution.

Is Klor-Con M suitable for a 505(b)(2) reformulation?

Potentially, if the proposed product differs materially from the reference product and requires reliance on existing findings combined with new data. A 505(b)(2) strategy may be relevant for a new dosage form, delivery system, or administration route, but it carries greater development and clinical justification requirements than a conventional ANDA.

Can a potassium chloride liquid replace Klor-Con M automatically?

No. A liquid potassium chloride product is a different dosage form and may have different dosing, release, labeling, and substitution status. Pharmacy substitution depends on FDA therapeutic-equivalence determinations and applicable state law.

What is the strongest commercial differentiation for a new Klor-Con M competitor?

The most defensible opportunities are reliable supply, AB-rated generic status, smaller or easier-to-swallow dosage forms, flexible dosing, and demonstrated manufacturing consistency. A new excipient combination alone is unlikely to create durable differentiation without a meaningful release, tolerability, or administration benefit.

References

1. U.S. Food and Drug Administration. (2023a). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

2. U.S. Food and Drug Administration. (2024a). Klor-Con M potassium chloride extended-release tablets: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024b). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files.